Evidence map›Paper›PMID 32817339›Full record

ArticleThe Journal of biological chemistry2020

Atypical TRAV1-2

Wael Awad, Erin W Meermeier, Maria L Sandoval-Romero, Jérôme Le Nours, Aneta H Worley, Megan D Null, Ligong Liu, James McCluskey, David P Fairlie, David M Lewinsohn and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Recognition of the antigen-presenting molecule MR1 by a Vδ3Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Wael AwadInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-7597-2133
Erin W MeermeierDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon, USA.
Maria L Sandoval-RomeroInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Jérôme Le NoursInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Aneta H WorleyVeterans Affairs Portland Health Care Center, Portland, Oregon, USA.
Megan D NullDepartment of Pediatrics, Oregon Health & Science University, Portland, Oregon, USA.
Ligong LiuInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
James McCluskeyDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia.
David P FairlieInstitute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
David M LewinsohnDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon, USA.
Jamie RossjohnInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia Jamie.rossjohn@monash.edu.ORCID 0000-0002-2020-7522
Australian Regenerative Medicine Institute · AUOregon Health & Science University · USThe University of Queensland · AUDiscovery Institute · USThe University of Melbourne · AUVA Portland Health Care System · US

Funding

Multidisciplinary Research Training in Pulmonary MedicineT32HL083808 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., SLATORE, CHRISTOPHER G. · 2008 to 2025
$5.3M
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. TuberculosisR01AI134790 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., WALZL, GERHARD · 2018 to 2022
$3.3M
Investigating the basis of MAIT cell antigen potencyR01AI148407 · NIAID · UNIVERSITY OF MELBOURNE · PI MCCLUSKEY, JAMES · 2020 to 2024
$2.7M
BLRD VA I01 BX000533NHLBI NIH HHS T32 HL083808NIAID NIH HHS R01 AI134790NIAID NIH HHS R01 AI148407
6 · The paper itself

Abstract

MR1 presents vitamin B-related metabolites to mucosal associated invariant T (MAIT) cells, which are characterized, in part, by the TRAV1-2

Indexed as

Amino Acid SequenceAntigen PresentationBinding SitesCrystallography, X-RayHistocompatibility Antigens Class IHumansMinor Histocompatibility AntigensMolecular Docking SimulationProtein RefoldingProtein Structure, TertiaryReceptors, Antigen, T-Cell, alpha-betaRibitolSurface Plasmon ResonanceT-LymphocytesUracil5-(2-oxopropylideneamino)-6-d-ribitylaminouracilHistocompatibility Antigens Class IMinor Histocompatibility AntigensMR1 protein, humanReceptors, Antigen, T-Cell, alpha-betaRibitolUracil: Antigen presentationatypical MAIT TCRcrystal structureimmunologyMAITmajor histocompatibility complex (MHC)MHC-related molecule (MR1)protein structurereceptor structure-functionT-cell receptor (TCR)

Identifiers

PMID32817339
PMCPMC7573270
OpenAlexW3049436692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.